Another GLP-1 ETF With a Passive Approach An alternative in the GLP-1 ETF space is the Amplify Weight Loss Drug & Treatment ETF (NYSEARCA: THNR)
Inhibition of pRb phosphorylation and cell cycle progression by an Antennapedia-p16INK4A fusion peptide in pancreatic cancer cells
Research published in major cardiology journals has indicated that GLP-1 therapy may reduce the need for additional cholesterol-lowering medications in some patients, though this should never replace statin therapy without direct physician guidance
As with other incretin-based therapies, the safety profile of retatrutide is closely linked to the dose level administered
Dec 21, 2025 Women face unique hormonal challenges that accelerate aging, reduce energy, and affect quality of life - declining estrogen after 35, menopause symptoms, metabolic slowdown, bone density loss, and skin aging
Start with the lowest dose and increase gradually as tolerated